Blinatumomab User Reviews & Ratings
Brand names: Blincyto
Blinatumomab has an average rating of 10.0 out of 10 from a total of 2 reviews on Drugs.com. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | 2 reviews for Acute Lymphoblastic Leukemia | 26 medications | |
| Add your review | |||
- blessed
- Taken for 6 months to 1 year
- September 27, 2023
Blincyto (blinatumomab) for Acute Lymphoblastic Leukemia "I have had great results from having Blincyto treatments. I have never experienced any side effects so far."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about blinatumomab
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: CD19 monoclonal antibodies
- Breastfeeding
- En español
For Acute Lymphoblastic Leukemia "Brought 11yo daughter into remission of Acute Lymphoblastic Leukemia. Received a total of 6 rounds of Blina. Due to extreme sensitivity and several complications from traditional chemo drugs. Still in remission and in maintenance therapy. She tolerated it well. She experienced headaches and lethargy the first week. But the remaining 28 days were okay."